HIV Vaccine Setback: NIAID Halts PAVE 100 Study, But Smaller Trial Planned
The National Institute of Allergy and Infectious Diseases will not move forward with plans for its large-scale Phase IIb HIV vaccine study, though a smaller study is being designed to examine viral response, the center announced July 17
You may also be interested in...
The AIDS vaccine search got its first real injection of good news with a positive trial of a "prime-boost" strategy tested in Thailand
Six-year U.S. Army/NIH-sponsored study conducted in 16,000-plus Thai adults shows 31.2% decreased risk of infection, but better efficacy is needed.
Plans for PAVE 100, the National Institute on Allergy and Infectious Diseases' Phase IIb HIV vaccine study, remain on hold until the next wave of Merck's STEP data - also expected to aid preclinical vaccine development - is released, researchers say